Evidence supporting the use of: Pine bark
For the health condition: Migraine

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Pine bark extract, particularly from the French maritime pine (Pinus pinaster), is known commercially as Pycnogenol. Its use in migraine management is primarily supported by emerging scientific evidence rather than a long-standing traditional application. Pine bark extract is rich in proanthocyanidins, a class of polyphenols with antioxidant and anti-inflammatory properties, which are hypothesized to contribute to its therapeutic effects. A few small clinical studies have investigated the efficacy of pine bark extract in reducing migraine frequency and severity. One pilot study published in 2013 found that supplementation with Pycnogenol led to a reduction in the frequency and intensity of migraine attacks among a small group of young patients. The proposed mechanisms include improved endothelial function and reduced oxidative stress, both of which are factors implicated in migraine pathophysiology. However, the overall body of evidence remains limited. The existing studies are generally small, sometimes lacking rigorous controls or blinding, and are not yet sufficient to establish pine bark extract as a proven treatment for migraines. Larger and more robust randomized controlled trials are necessary to confirm its efficacy and safety profile for this indication. In summary, while pine bark extract has shown some promise in preliminary scientific research related to migraine management, the evidence is not yet strong or extensive. It should not replace established migraine therapies, but may be considered as an adjunct under medical supervision.

More about pine bark
More about Migraine